Sign in or create an account to add this stock to your watchlist.
About iRhythm (NASDAQ:IRTC)
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRTC
CUSIPN/A
Phone415-632-5700
Debt
Debt-to-Equity Ratio0.45
Current Ratio6.59
Quick Ratio6.48
Price-To-Earnings
Trailing P/E Ratio-53.42
Forward P/E Ratio-46.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$98.51 million
Price / Sales17.05
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book23.10
Profitability
EPS (Most Recent Fiscal Year)($1.30)
Net Income$-29,420,000.00
Net Margins-32.73%
Return on Equity-43.37%
Return on Assets-26.92%
Miscellaneous
Employees575
Outstanding Shares23,600,000
iRhythm (NASDAQ:IRTC) Frequently Asked Questions
What is iRhythm's stock symbol?
iRhythm trades on the NASDAQ under the ticker symbol "IRTC."
How were iRhythm's earnings last quarter?
iRhythm (NASDAQ:IRTC) released its quarterly earnings data on Wednesday, May, 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.11. The company had revenue of $30.60 million for the quarter, compared to analyst estimates of $29.07 million. iRhythm had a negative return on equity of 43.37% and a negative net margin of 32.73%. iRhythm's revenue for the quarter was up 43.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.24) earnings per share. View iRhythm's Earnings History.
When is iRhythm's next earnings date?
What price target have analysts set for IRTC?
7 brokers have issued 1 year price targets for iRhythm's stock. Their predictions range from $60.00 to $80.00. On average, they expect iRhythm's share price to reach $71.1667 in the next year. View Analyst Ratings for iRhythm.
What are Wall Street analysts saying about iRhythm stock?
Here are some recent quotes from research analysts about iRhythm stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (5/8/2018)
- 2. Northland Securities analysts commented, "We note that this was a physician-initiated study and funded by Bardy. Also, it is important to take this study within the context of an initial study which could provide clues for a larger head-head study, providing important clues for the sensitivity & specificity of R-R wave vs. P-wave analysis in ambulatory ECG monitoring." (4/16/2018)
- 3. Canaccord Genuity analysts commented, "We expect these data, assuming the read-out of the full study data follows suit (which we expect), will build IRTC’s case with payers, paving the way ultimately for prospective screening with Zio in a brand new, 3- million-patient TAM. While not in our model at all, we think over time, payors will cover Zio for screening of high-risk patients defined by the mSToPs study. We reiterate our BUY rating and $59 price target." (11/14/2017)
Who are some of iRhythm's key competitors?
Some companies that are related to iRhythm include Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS) and Intersect ENT (XENT).
Who are iRhythm's key executives?
iRhythm's management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 62)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 50)
- Mr. David A. Vort, Exec. VP of Sales (Age 52)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 45)
- Ms. Judith C. Lenane RN, MHA, Chief Clinical Officer and Exec. VP of Operations (Age 59)
When did iRhythm IPO?
(IRTC) raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Has iRhythm been receiving favorable news coverage?
Media headlines about IRTC stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. iRhythm earned a daily sentiment score of 0.23 on Accern's scale. They also gave news stories about the company an impact score of 47.65 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are iRhythm's major shareholders?
iRhythm's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.87%), Franklin Resources Inc. (4.52%), Redmile Group LLC (3.09%), Wells Fargo & Company MN (2.95%), JPMorgan Chase & Co. (2.65%) and Millennium Management LLC (2.63%). Company insiders that own iRhythm stock include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Institutional Ownership Trends for iRhythm.
Which major investors are selling iRhythm stock?
IRTC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Redmile Group LLC, Next Century Growth Investors LLC, Massachusetts Financial Services Co. MA, Pier Capital LLC, Lord Abbett & CO. LLC, Osterweis Capital Management Inc. and FIL Ltd. Company insiders that have sold iRhythm company stock in the last year include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Insider Buying and Selling for iRhythm.
Which major investors are buying iRhythm stock?
IRTC stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Millennium Management LLC, Eagle Asset Management Inc., JPMorgan Chase & Co., Point72 Asset Management L.P., New York State Common Retirement Fund, Royal Bank of Canada and Rock Springs Capital Management LP. View Insider Buying and Selling for iRhythm.
How do I buy shares of iRhythm?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iRhythm's stock price today?
One share of IRTC stock can currently be purchased for approximately $71.16.
How big of a company is iRhythm?
iRhythm has a market capitalization of $1.64 billion and generates $98.51 million in revenue each year. The company earns $-29,420,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. iRhythm employs 575 workers across the globe.
How can I contact iRhythm?
iRhythm's mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for iRhythm (IRTC)
MarketBeat's community ratings are surveys of what our community members think about iRhythm and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
iRhythm (NASDAQ:IRTC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for iRhythm in the last 12 months. Their average twelve-month price target is $71.1667, suggesting that the stock has a possible upside of 0.01%. The high price target for IRTC is $80.00 and the low price target for IRTC is $60.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.71 | 2.80 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $71.1667 | $71.1667 | $67.50 | $62.00 |
| Price Target Upside: | 0.01% upside | 13.03% upside | 13.10% upside | 28.28% upside |
iRhythm (NASDAQ:IRTC) Consensus Price Target History
iRhythm (NASDAQ:IRTC) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
iRhythm (NASDAQ:IRTC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
iRhythm (NASDAQ IRTC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.05%
Institutional Ownership Percentage: 98.78%
iRhythm (NASDAQ IRTC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2018 | Derrick Sung | Insider | Sell | 10,000 | $70.00 | $700,000.00 | 23,858 |  |
| 5/8/2018 | Kevin M King | Insider | Sell | 80,000 | $65.91 | $5,272,800.00 | 218,146 | |
| 3/9/2018 | Vijay K. Lathi | Director | Sell | 114,018 | $66.44 | $7,575,355.92 | | |
| 3/8/2018 | David A Vort | EVP | Sell | 935 | $67.01 | $62,654.35 | 22,221 | |
| 2/26/2018 | Kevin M King | Insider | Sell | 60,000 | $64.52 | $3,871,200.00 | 201,842 | |
| 2/23/2018 | Raymond W Scott | Director | Sell | 8,499 | $65.55 | $557,109.45 | 8,499 | |
| 2/21/2018 | Vijay K Lathi | Director | Sell | 169,000 | $62.41 | $10,547,290.00 | | |
| 1/5/2018 | Matthew C Garrett | CFO | Sell | 42,910 | $59.17 | $2,538,984.70 | 36,085 | |
| 12/7/2017 | Vijay K. Lathi | Director | Sell | 150,000 | $52.57 | $7,885,500.00 | | |
| 12/5/2017 | Vijay K. Lathi | Director | Sell | 57,430 | $52.41 | $3,009,906.30 | | |
| 12/4/2017 | Matthew C Garrett | CFO | Sell | 1,193 | $55.00 | $65,615.00 | | |
| 11/17/2017 | Vijay K Lathi | Director | Sell | 225,000 | $52.10 | $11,722,500.00 | | |
| 11/6/2017 | Kevin M King | Insider | Sell | 60,000 | $51.85 | $3,111,000.00 | 103,042 | |
| 9/13/2017 | Vijay K Lathi | Director | Sell | 34,613 | $49.51 | $1,713,689.63 | 1,405 | |
| 9/12/2017 | David A. Vort | EVP | Sell | 5,000 | $48.76 | $243,800.00 | | |
| 9/7/2017 | Raymond W Scott | Director | Sell | 8,088 | $48.00 | $388,224.00 | 8,088 | |
| 9/6/2017 | Raymond W Scott | Director | Sell | 4,661 | $48.02 | $223,821.22 | 4,661 | |
| 8/28/2017 | Raymond W Scott | Director | Sell | 12,749 | $45.30 | $577,529.70 | 12,749 | |
| 8/7/2017 | Raymond W. Scott | Director | Sell | 52,903 | $43.59 | $2,306,041.77 | | |
| 7/11/2017 | Kevin M. King | Insider | Sell | 110,000 | $42.08 | $4,628,800.00 | | |
| 7/10/2017 | Matthew C. Garrett | CFO | Sell | 25,086 | $42.06 | $1,055,117.16 | | |
| 6/8/2017 | Synergy Life Science Partners | Major Shareholder | Sell | 350,000 | $37.43 | $13,100,500.00 | | |
| 6/8/2017 | Vijay K Lathi | Director | Sell | 430,624 | $37.59 | $16,187,156.16 | | |
| 5/16/2017 | Vijay K Lathi | Director | Sell | 645,000 | $34.70 | $22,381,500.00 | | |
(Data available from 1/1/2013 forward)
iRhythm (NASDAQ IRTC) News Headlines
| Source: |
|
iRhythm (NASDAQ:IRTC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
iRhythm (NASDAQ:IRTC) Income Statement, Balance Sheet and Cash Flow Statement
iRhythm (NASDAQ IRTC) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
